Fusion Antibodies (FAB) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Apr 2008 07:00 AM
RNS
Net Asset Value(s)
13 Mar 2008 10:48 AM
RNS
Holding(s) in Company
04 Feb 2008 07:00 AM
RNS
Net Asset Value(s)
21 Jan 2008 05:50 PM
RNS
Holding(s) in Company
22 Nov 2007 07:02 AM
RNS
Director/PDMR Shareholding
22 Nov 2007 07:01 AM
RNS
Change of Adviser
22 Oct 2007 07:01 AM
RNS
Net Asset Value(s)
28 Sep 2007 10:27 AM
RNS
Interim Results
19 Sep 2007 10:50 AM
RNS
Holding(s) in Company
16 Aug 2007 07:00 AM
RNS
Rule 26 Notification
03 Aug 2007 01:58 PM
RNS
Net Asset Value(s)
01 Aug 2007 03:32 PM
RNS
Result of AGM
11 Jul 2007 08:16 AM
RNS
Update on development
29 Jun 2007 07:00 AM
RNS
Final Results
25 Jun 2007 11:36 AM
RNS
Acquisition
18 Jun 2007 07:00 AM
RNS
Acquisition
14 Jun 2007 07:00 AM
RNS
Acquisition
04 Jun 2007 07:01 AM
RNS
Acquisition
22 May 2007 03:27 PM
RNS
Holding(s) in Company
21 May 2007 03:22 PM
RNS
Director/PDMR Shareholding
30 Apr 2007 07:01 AM
RNS
Acquisition
23 Apr 2007 07:00 AM
RNS
Net Asset Value(s)
09 Feb 2007 05:59 PM
RNS
Director/PDMR Shareholding
29 Jan 2007 02:36 PM
RNS
Director/PDMR Shareholding
22 Jan 2007 07:01 AM
RNS
Appointment of Director
22 Jan 2007 07:01 AM
RNS
Net Asset Value(s)
19 Dec 2006 03:48 PM
RNS
Voting rights and capital
15 Dec 2006 04:25 PM
RNS
Director/PDMR Shareholding
15 Dec 2006 07:00 AM
RNS
Admission to AIM

Fusion Antibodies is a biotechnology company that specializes in antibody development services for the healthcare industry. The company was founded in 2001 as a spin-out from Queen's University Belfast and is headquartered in Belfast, Northern Ireland. Fusion Antibodies offers antibody discovery, engineering, supply, and cell line development. It has developed proprietary technology platforms such as CDRx® for antibody humanization, RAMP® for affinity maturation, and ADD™ for developability optimization.

FAB share price launched at 165p in 2017.

UK 100

Latest directors dealings